Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma

References

• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35–S50.
   PubMed Web of Science ®Google Scholar
• WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed December 1, 2015).
   Google Scholar
• Song T. Recent advances in surgical treatment of hepatocellular carcinoma. Drug Discov Ther 2015;9:319–30.
   PubMedGoogle Scholar
• Tanaka T, Sugawara Y, Kokudo N. Liver transplantation and autoimmune hepatitis. Intractable Rare Dis Res 2015;4:33–8.
   PubMedGoogle Scholar
• Jiang W, Li J, Guo Q, Sun J, Chen C, Shen Z. Liver transplantation for hepatocellular carcinoma. Drug Discov Ther 2015;9:331–4.
   PubMedGoogle Scholar
• Akamatsu N, Sugawara Y, Kokudo N. Acute liver failure and liver transplantation. Intractable Rare Dis Res 2013;2:77–87.
   PubMedGoogle Scholar
• Sasaki K, Matsuda M, Ohkura Y, Kawamura Y, Inoue M, Hashimoto M, Ikeda K, Kumada H, Watanabe G. The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size. World J Surg 2015;39:1134–41.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Lei J, Li B, Yan L, Wang W, Wei Y, Cheng K. Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule <2 cm): a single-center study. Eur J Gastroenterol Hepatol 2014;26:339–44.
   PubMed Web of Science ®Google Scholar
• Guo R, Feng X, Xiao S, Yan J, Xia F, Ma K, Li X. Short- and long-term outcomes of hepatectomy with or without radiofrequency-assist for the treatment of hepatocellular carcinomas: a retrospective comparative cohort study. Biosci Trends 2015;9:65–72.
   PubMed Web of Science ®Google Scholar
• Ge S, Huang D. Systemic therapies for hepatocellular carcinoma. Drug Discov Ther 2015;9:352–62.
   PubMedGoogle Scholar
• Zhang W, Zhao G, Wei K, Zhang Q, Ma W, Song T, Wu Q, Zhang T, Kong D, Li Q. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends 2014;8:333–8.
   PubMed Web of Science ®Google Scholar
• Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37–47.
   PubMed Web of Science ®Google Scholar
• Sun H, Song T. Hepatocellular carcinoma: advances in diagnostic imaging. Drug Discov Ther 2015;9:310–8.
   PubMedGoogle Scholar
• Song PP, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016;22:262–74.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Seo YS, Lee KG, Hyun JJ, An H, Keum B, Kim JH, Yim HJ, Jeen YT, Lee HS, Chun HJ, Um SH, Kim CD, Ryu HS. Serum aminotransferase levels instead of etiology affects the accuracy of transient elastography in chronic viral hepatitis patients. J Gastroenterol Hepatol 2011;26:492–500.
   PubMed Web of Science ®Google Scholar
• Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P, FIBROSTIC study group. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53:1013–21.
   PubMed Web of Science ®Google Scholar
• Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251–9.
   PubMed Web of Science ®Google Scholar
• Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int 2012;32:1053–63.
   PubMed Web of Science ®Google Scholar
• Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N, Dong J, Yao L, Tang W. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. Biosci Trends 2013;7:1–6.
   PubMed Web of Science ®Google Scholar
• Japan Society of Hepatology. Clinical practice guidelines for hepatocellular carcinoma (2013 version). Kanehara T, Japan, 2013. (in Japanese).
   Google Scholar
• National Health and Family Planning Commission. The Guideline on Diagnosis and Treatment for Primary Liver Cancer (2011 version, in Chinese). http://www.moh.gov.cn/mohyzs/s3586/201110/53153.shtml (accessed on December 16, 2015)
   Google Scholar
• Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–74.
   PubMed Web of Science ®Google Scholar
• Barletta E, Tinessa V, Daniele B. [Screening of hepatocellular carcinoma: role of the alpha-fetoprotein (AFP) and ultrasonography]. Recenti Prog Med 2005;96:295–9.
   PubMedGoogle Scholar
• Zhou XD, Tang ZY, Fan J, Zhou J, Wu ZQ, Qin LX, Ma ZC, Sun HC, Qiu SJ, Yu Y, Ren N, Ye QH, Wang L, Ye SL. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009;135:1073–80.
   PubMed Web of Science ®Google Scholar
• Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008;2:17–30.
   PubMed Web of Science ®Google Scholar
• Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C, Satomura S. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol 2014;49:555–63.
   PubMed Web of Science ®Google Scholar
• Gao J, Feng X, Inagaki Y, Song P, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends 2012;6:153–9.
   PubMed Web of Science ®Google Scholar
• Zhang K, Song P, Gao J, Li G, Zhao X, Zhang S. Perspectives on a combined test of multi serum biomarkers in China: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Drug Discov Ther 2014;8:102–9.
   PubMedGoogle Scholar
• Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110–8.
   PubMed Web of Science ®Google Scholar
• Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:1541–8.
   PubMed Web of Science ®Google Scholar
• Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, Ogihara T, Kamada T. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993;38:2170–6.
   PubMed Web of Science ®Google Scholar
• Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999;94:650–4.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Bae KW, Seo PJ, Jeong IK, Kim JH, Lee BH, Bang KT, Kim DW, Song IH. Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma–using ROC curve. Korean J Hepatol 2006;12:404–11.
   PubMedGoogle Scholar
• Yoon YJ, Han KH, Kim C, Chon CY, Moon YM, Han CH, Choi HJ, Kim YS, Han JY, Kim HS. [Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma]. Taehan Kan Hakhoe Chi 2002;8:465–71.
   PubMedGoogle Scholar
• Korean Liver Cancer Study Group, National Cancer Center Korea. 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 2015;16:465–522.
   PubMed Web of Science ®Google Scholar
• Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, Yang Z, Cai J, Li H, Chen J, Zhong S, Mohanti SR, Lopez-Soler R, Millis JM, Huang J, Zhang H. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010;59:1687–93.
   PubMed Web of Science ®Google Scholar
• Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008;19:353–8.
   PubMed Web of Science ®Google Scholar
• Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, Dentico P, Antonaci S. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta 2007;383:147–52.
   PubMed Web of Science ®Google Scholar
• Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483–90.
   PubMed Web of Science ®Google Scholar
• Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res 2013;33:1013–21.
   PubMed Web of Science ®Google Scholar
• Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012;13:817–26.
   PubMed Web of Science ®Google Scholar
• Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, Loffredo CA, Forgues M, Huang H, Xing XJ, Ren N, Dong QZ, Zhou HJ, Ren ZG, Zhao NQ, Wang XW, Tang ZY, Qin LX, Ye QH. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res 2013;19:3944–54.
   PubMed Web of Science ®Google Scholar
• Berindan-Neagoe I, Monroig Pdel C, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin 2014;64:311–36.
   PubMed Web of Science ®Google Scholar
• Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010;70:9798–807.
   PubMed Web of Science ®Google Scholar
• Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29:4781–8.
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T, Doki Y, Mori M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012;56:167–75.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011;21:401–16.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Hou JL, Chutaputti A. Asia Pacific working party on prevention of hepatocellular C. Hepatocellular carcinoma in the Asia Pacific region. J Gastroenterol Hepatol 2009;24:346–53.
   PubMed Web of Science ®Google Scholar
• Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer 2013;2:31–9.
   PubMed Web of Science ®Google Scholar
• Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417–22.
   PubMed Web of Science ®Google Scholar
• Cui R, Wang B, Ding H, Shen H, Li Y, Chen X. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. Chin Med J (Engl) 2002;115:42–5.
   PubMed Web of Science ®Google Scholar
• Cui R, He J, Zhang F, Wang B, Ding H, Shen H, Li Y, Chen X. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer 2003;88:1878–82.
   PubMed Web of Science ®Google Scholar
• Song P, Feng X, Inagaki Y, Song T, Zhang K, Wang Z, Zheng S, Ma K, Li Q, Kong D, Wu Q, Zhang T, Zhao X, Hasegawa K, Sugawara Y, Kokudo N, Tang W, Japan-China Joint Team for Medical Research and Cooperation on HCC. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: a multi-center case-controlled study of 1,153 subjects. Biosci Trends 2014;8:266–73.
   PubMed Web of Science ®Google Scholar
• Song P. Standardizing management of hepatocellular carcinoma in China: devising evidence-based clinical practice guidelines. Biosci Trends 2013;7:250–2.
   PubMed Web of Science ®Google Scholar
• Song PP, Gao JJ, Kokudo N, Dong JH, Tang W. “Knowledge into action” exploration of an appropriate approach for constructing evidence-based clinical practice guidelines for hepatocellular carcinoma. Biosci Trends 2012;6:147–52.
   PubMed Web of Science ®Google Scholar